Research ArticleOriginal Research
Tobramycin Inhalation Powder in Cystic Fibrosis Patients: Response by Age Group
David E Geller, Samya Z Nasr, Simon Piggott, Ellie He, Gerhild Angyalosi and Mark Higgins
Respiratory Care August 2013, respcare.02264; DOI: https://doi.org/10.4187/respcare.02264
David E Geller
1Florida State University College of Medicine (Orlando Campus), Orlando, Florida, USA.
MDSamya Z Nasr
2Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, USA.
MDSimon Piggott
3Novartis Horsham Research Centre, Horsham, West Sussex, UK.
PhDEllie He
4Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
PhDGerhild Angyalosi
5Novartis Pharma AG, Basel, Switzerland.
MDMark Higgins
3Novartis Horsham Research Centre, Horsham, West Sussex, UK.
MDIn this issue
Respiratory Care
Vol. 69, Issue 4
1 Apr 2024
Tobramycin Inhalation Powder in Cystic Fibrosis Patients: Response by Age Group
David E Geller, Samya Z Nasr, Simon Piggott, Ellie He, Gerhild Angyalosi, Mark Higgins
Respiratory Care Aug 2013, respcare.02264; DOI: 10.4187/respcare.02264